A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Public ClinicalTrials.gov record NCT07213791. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy With LY4337713 in Adults With FAP-Positive Solid Tumors (FiREBOLT)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713. In addition, this study will evaluate how much LY4337713 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. For each participant, the study will last about 5 years.
Study identification
- NCT ID
- NCT07213791
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 241 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 21, 2025
- Primary completion
- Jun 30, 2028
- Completion
- Feb 28, 2033
- Last update posted
- Sep 3, 2026
2025 – 2033
United States locations
- U.S. sites
- 20
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Hoag Memorial Hospital Presbyterian | Newport Beach | California | 92663 | Recruiting |
| Stanford University Medical Center | Stanford | California | 94305 | Recruiting |
| Biogenix Molecular, LLC | Miami | Florida | 33165 | Completed |
| Moffitt | Tampa | Florida | 33612 | Recruiting |
| Indiana University (IU) School of Medicine | Indianapolis | Indiana | 46202 | Recruiting |
| United Theranostics | Glen Burnie | Maryland | 21061 | Recruiting |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | Recruiting |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | Not yet recruiting |
| Barbara Ann Karmanos Cancer Institute | Detroit | Michigan | 48201 | Recruiting |
| BAMF Health Inc. | Grand Rapids | Michigan | 49503 | Recruiting |
| Mayo Clinic - Rochester | Rochester | Minnesota | 55905 | Not yet recruiting |
| Washington University School of Medicine in St. Louis | St Louis | Missouri | 63110 | Recruiting |
| New York University (NYU) Clinical Cancer Center | New York | New York | 10016 | Recruiting |
| David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | Recruiting |
| Duke University Medical Center | Durham | North Carolina | 27710 | Recruiting |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | Recruiting |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | Recruiting |
| Texas Oncology - DFW (Sammons CC) | Dallas | Texas | 75246 | Recruiting |
| Baylor College of Medicine | Houston | Texas | 77030 | Not yet recruiting |
| University of Wisconsin - Carbone Cancer Center | Madison | Wisconsin | 53792 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07213791, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 3, 2026 · Synced Sep 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07213791 live on ClinicalTrials.gov.